stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Gross margin
Natera, Inc.'s gross margin over the twelve months to 30 September 2026 was 0.00%, down 64.8 percentage points from fiscal 2025 (64.8%). Over the past ten years it has ranged from 33.4% (fiscal 2017) to 64.8% (fiscal 2025) — the current reading is the highest in ten years. That is below the Diagnostics & Research industry median of 48.3% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 64.8% | 4.45 |
| FY2024 | 60.3% | 14.78 |
| FY2023 | 45.5% | 1.15 |
| FY2022 | 44.4% | (4.72) |
| FY2021 | 49.1% | 1.17 |
| FY2020 | 47.9% | 5.96 |
| FY2019 | 42.0% | 6.41 |
| FY2018 | 35.6% | 2.14 |
| FY2017 | 33.4% | (2.79) |
| FY2016 | 36.2% | (4.52) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | (64.46) |
| Jun 2026 | 64.5% | (0.25) |
| Mar 2026 | 64.7% | (2.22) |
| Dec 2025 | 66.9% | 2.02 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| ILMN Illumina, Inc. compare | 67.9% |
| IDXX IDEXX Laboratories, Inc. compare | 62.7% |
| MTD Mettler-Toledo International, Inc. compare | 60.3% |
| A Agilent Technologies, Inc. compare | 53.8% |
| WAT Waters Corporation compare | 49.5% |
| DGX Quest Diagnostics Incorporated compare | 33.1% |
| IQV IQVIA Holdings Inc. compare | 33.1% |
| LH Labcorp Holdings Inc. compare | 29.0% |
| NTRA Natera, Inc. | 0.00% |
| Diagnostics & Research industry median | 48.3% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement